Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 4/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 8/20 | 0.40 |
| ▸ | GRM5 | P41594 | 7/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.38 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4150805 | 0.89 | TGFBR1 (0.41) | JAK1NAMPTSOS1 | |
| SCHEMBL4154926 | 0.88 | JAK1 (0.55) | JAK1CYP11B2NAMPTGRM1GRM5 | |
| SCHEMBL4156942 | 0.85 | ESR2 (0.41) | JAK1CYP11B2NAMPTGRM5 | |
| SCHEMBL4167336 | 0.85 | NR1H2 (0.41) | JAK1CYP11B2GRM5 | |
| SCHEMBL4159298 | 0.83 | TGFBR1 (0.41) | — | |
| SCHEMBL3726133 | 0.78 | ROCK2 (0.39) | JAK1 | |
| SCHEMBL4156960 | 0.78 | TGFBR1 (0.43) | JAK1 | |
| SCHEMBL3724252 | 0.78 | TGFBR1 (0.45) | NAMPT | |
| SCHEMBL3667334 | 0.77 | TGFBR1 (0.43) | JAK1 | |
| SCHEMBL3732917 | 0.77 | TGFBR1 (0.43) | SOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | JAK1 29/4885CYP11B2 1994/4885NAMPT 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.